| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Institut National de la Santé et de la Recherche Médicale U517, Facultés de Médicine et de Pharmacie, 21033 Dijon Cédex, France
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a new cytokine that was proposed to specifically induce apoptosis of cancer cells. In tumor cells that are resistant to the cytokine, subtoxic concentrations of chemotherapeutic drugs can restore the response to TRAIL. The present study further explores the mechanisms that determine tumor cell sensitivity to TRAIL by comparing four human colon carcinoma cell lines. We show that colon cancer cell sensitivity to TRAIL-induced apoptosis and cytotoxicity correlates with the expression of the death receptors TRAIL-R1 and TRAIL-R2 at the cell surface, as determined by flow cytometry, whereas the two decoy receptors TRAIL-R3 and TRAIL-R4 can be detected only in permeabilized cells. Clinically relevant concentrations of cisplatin and doxorubicin sensitize the most resistant colon cancer cell lines to TRAIL-induced cell death without modifying the expression nor the localization of TRAIL receptors in these cells. TRAIL induces the activation of procaspase-8 and triggers caspase-dependent apoptosis of colon cancer cells. Cytotoxic drugs lower the signaling threshold required for TRAIL-induced procaspase-8 activation. In turn, caspase-8 cleaves Bid, a BH3 domain-containing proapoptotic molecule of the Bcl-2 family, and activates effector caspases. Together, these data indicate that chemotherapeutic drugs sensitize colon tumor cells to TRAIL-mediated caspase-8 activation and apoptosis.
This article has been cited by other articles:
|
|
 |
|
  A. Soeda, Y. Morita-Hoshi, H. Makiyama, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka, S. Yamagata, N. Takahashi, I. Hyodo, et al. Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer Jpn. J. Clin. Oncol., October 1, 2009; (2009) hyp112v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Mom, J. Verweij, C. N.A.M. Oldenhuis, J. A. Gietema, N. L. Fox, R. Miceli, F. A.L.M. Eskens, W. J. Loos, E. G.E. de Vries, and S. Sleijfer Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study Clin. Cancer Res., September 1, 2009; 15(17): 5584 - 5590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-X. Wu and Y. Kakehi Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner Clin. Cancer Res., March 15, 2009; 15(6): 2039 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Hotte, H. W. Hirte, E. X. Chen, L. L. Siu, L. H. Le, A. Corey, A. Iacobucci, M. MacLean, L. Lo, N. L. Fox, et al. A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3450 - 3455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Oliver, A. F. LoBuglio, K. R. Zinn, H. Kim, L. Nan, T. Zhou, W. Wang, and D. J. Buchsbaum Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 Clin. Cancer Res., April 1, 2008; 14(7): 2180 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. DeRosier, S. M. Vickers, K. R. Zinn, Z. Huang, W. Wang, W. E. Grizzle, J. Sellers, C. R. Stockard Jr., T. Zhou, P. G. Oliver, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth Mol. Cancer Ther., December 1, 2007; 6(12): 3198 - 3207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yoshida, T. Maoka, S. K. Das, K. Kanazawa, M. Horinaka, M. Wakada, Y. Satomi, H. Nishino, and T. Sakai Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mol. Cancer Res., June 1, 2007; 5(6): 615 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Testa and R. Riccioni Deregulation of apoptosis in acute myeloid leukemia Haematologica, January 1, 2007; 92(1): 81 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Elankumaran, D. Rockemann, and S. K. Samal Newcastle Disease Virus Exerts Oncolysis by both Intrinsic and Extrinsic Caspase-Dependent Pathways of Cell Death. J. Virol., August 1, 2006; 80(15): 7522 - 7534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Hsiao, W.-S. Wang, P.-M. Chen, and Y. Su Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively Carcinogenesis, May 1, 2006; 27(5): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP Mol. Cancer Ther., December 1, 2005; 4(12): 2026 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Meurette, L. Lefeuvre-Orfila, A. Rebillard, D. Lagadic-Gossmann, and M.-T. Dimanche-Boitrel Role of Intracellular Glutathione in Cell Sensitivity to the Apoptosis Induced by Tumor Necrosis Factor {alpha}-Related Apoptosis-Inducing Ligand/Anticancer Drug Combinations Clin. Cancer Res., April 15, 2005; 11(8): 3075 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Sinicrope, R. C. Penington, and X. M. Tang Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells Clin. Cancer Res., December 15, 2004; 10(24): 8284 - 8292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Reddy, W. S. Tsai, M. F. Ziauddin, J. Zuo, G. W. Cole Jr, J. B. Maxhimer, B. Fang, D. S. Schrump, and D. M. Nguyen Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamamoto, H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al. Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-{alpha}/5-Fluorouracil against Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2004; 10(23): 7884 - 7895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, and W. S. El-Deiry Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells J. Biol. Chem., September 17, 2004; 279(38): 40044 - 40052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lacour, A. Hammann, S. Grazide, D. Lagadic-Gossmann, A. Athias, O. Sergent, G. Laurent, P. Gambert, E. Solary, and M.-T. Dimanche-Boitrel Cisplatin-Induced CD95 Redistribution into Membrane Lipid Rafts of HT29 Human Colon Cancer Cells Cancer Res., May 15, 2004; 64(10): 3593 - 3598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1{beta}-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells Clin. Cancer Res., September 15, 2003; 9(11): 4255 - 4266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo Cancer Res., September 1, 2003; 63(17): 5390 - 5400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, S. Hilsenbeck, and Y. Gazitt Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL Blood, May 15, 2003; 101(10): 4078 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel Cancer Res., March 15, 2003; 63(6): 1365 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Strater, U. Hinz, H. Walczak, G. Mechtersheimer, K. Koretz, C. Herfarth, P. Moller, and T. Lehnert Expression of TRAIL and TRAIL Receptors in Colon Carcinoma: TRAIL-R1 Is an Independent Prognostic Parameter Clin. Cancer Res., December 1, 2002; 8(12): 3734 - 3740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Werner, E. de Vries, S. W. G. Tait, I. Bontjer, and J. Borst TRAIL Receptor and CD95 Signal to Mitochondria via FADD, Caspase-8/10, Bid, and Bax but Differentially Regulate Events Downstream from Truncated Bid J. Biol. Chem., October 18, 2002; 277(43): 40760 - 40767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, X. Wang, A. Hernandez, M. R. Hellmich, Z. Gatalica, and B. M. Evers Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells J. Biol. Chem., September 20, 2002; 277(39): 36602 - 36610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohtsuka and T. Zhou Bisindolylmaleimide VIII Enhances DR5-mediated Apoptosis through the MKK4/JNK/p38 Kinase and the Mitochondrial Pathways J. Biol. Chem., August 2, 2002; 277(32): 29294 - 29303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Eid, R. W. Lewis, and M. V. Kumar Mifepristone Pretreatment Overcomes Resistance of Prostate Cancer Cells to Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL) Mol. Cancer Ther., August 1, 2002; 1(10): 831 - 840. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
